Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Summary

Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.

Timeline

Start

2015-03

Primary completion

2015-08

Completion

2015-08

Drugs

Indications